Received May 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | UNK | Y007472 | OT / LL |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | UNK | — | — |
No additional AEs; Caller reported a Patient received her 1st dose of VAQTA on 5/21/2024 and 2nd dose on 11/14/2024. The 2nd dose was administered 1 week too early. The Lot and expiration information under product tab is for the 2nd dose as that is the dose involved; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, previous drugs reactions and allergies were not reported. On 21-May-2024, the patient was vaccinated with the first dose of Hepatitis A Vaccine, Inactivated (VAQTA) administered as prophylaxis (Lot No., expiration date, exact quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). On 14-Nov-2024, the patient was vaccinated with the second dose of Hepatitis A Vaccine, Inactivated (VAQTA) 0.5 mL, strength reported as 25/0.5, administered intramuscular on the left thigh as prophylaxis (Lot No. Y007472 has been verified to be a valid lot number for [hepatitis a vaccine, inactivated], expiration date reported and upon internal validation established as 19-Oct-2025) (vaccination scheme frequency was not provided). It was stated that the second dose was administered 1 week too early (inappropriate schedule of product administration). No additional adverse event was reported (no adverse event).